Brian Pittman

Statistician 3 at Yale School of Medicine

Data updated

Papers

7 publications

Trials

0 clinical trials

Links

Website

Research Footprint

Brian Pittman appears in 7 tracked papers (2012–2025), most studied alongside Psilocybin and Salvia Divinorum, across Headache Disorders (Cluster & Migraine), Chronic Pain and Safety & Risk Management.

Most-cited paper: Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial (148 citations).

Frequent co-authors: Deepak Cyril D’Souza, Emmanuelle Schindler and Christopher Gottschalk.

Background & Research

Brian Pittman earned an MS in biostatistics from Columbia University in 1993 and has worked as a statistician with the Center for the Translational Neuroscience of Alcohol at Yale since 2004. His work focuses on the design, analysis, interpretation, and reporting of clinical and biomedical studies, including psychiatric challenge studies and psychedelic-related trials.

Key Impact

He is a coauthor on multiple Yale clinical trial papers in psilocybin research, including studies on migraine and cluster headache.

7

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

8 collaborators· click a node to visit their profile

Full network →

Compounds

PsilocybinSalvia Divinorum

Topics

Headache Disorders (Cluster & Migraine)Chronic PainSafety & Risk ManagementAnxiety DisordersDepressive DisordersNeuroimaging & Brain MeasuresMedicinal Chemistry & Drug DevelopmentMajor Depressive Disorder (MDD)MicrodosingPublic Health, Prevention & Behaviour ChangeAdolescentsHealthy VolunteersSet & SettingSuicidality

Top Collaborators

Affiliations

Institutions, companies, and organisations Brian Pittman is associated with.

VA Connecticut Healthcare System

government

The VA Connecticut Healthcare System provides comprehensive medical and mental health services to veterans across Connecticut, with campuses in West Haven and Newington. As part of the VA's expanding psychedelic research program, it participates in clinical trials investigating MDMA-assisted therapy and psilocybin for PTSD and related conditions affecting veterans.

View stakeholder →

Yale University

academic

In 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.

View stakeholder →